Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression

Journal of Pathology

Volumn 224, Issue 3, 2011, Pages 309-321

  Rajan, Neil ^a   Burn, John ^a   Langtry, James ^b   Sieber Blum, Maya ^a   Lord, Christopher J ^c   Ashworth, Alan ^c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

CYLD; cylindroma; DKK2; epigenetics; skin cancer

Indexed keywords

BETA CATENIN; CYLD ENZYME; DICKKOPF 2; GLYCOPROTEIN; HYDROLASE; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CYLINDROMA; GENE EXPRESSION; GENETIC ASSOCIATION; HIDRADENOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

ADENOMA, SWEAT GLAND; BETA CATENIN; CARCINOMA, ADENOID CYSTIC; CELL PROLIFERATION; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; GENOME-WIDE ASSOCIATION STUDY; GERM-LINE MUTATION; HUMANS; IMAGING, THREE-DIMENSIONAL; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM PROTEINS; PHENOTYPE; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SWEAT GLAND NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; WNT PROTEINS;

EID: 79958214511     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2896     Document Type: Article

References (38)

1. Rajan N, Langtry JA, Ashworth A, et al., Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction. Arch Dermatol 2009; 145: 1277-1284.
2. Michal M, Lamovec J, Mukensnabl P, et al., Spiradenocylindromas of the skin: tumors with morphological features of spiradenoma and cylindroma in the same lesion: report of 12 cases. Pathol Int 1999; 49: 419-425. (Pubitemid 29309672)
3. Brummelkamp TR, Nijman SM, Dirac AM, et al., Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003; 424: 797-801. (Pubitemid 37021711)
4. Kovalenko A, Chable-Bessia C, Cantarella G, et al., The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801-805. (Pubitemid 37021712)
5. Trompouki E, Hatzivassiliou E, Tsichritzis T, et al., CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424: 793-796. (Pubitemid 37021710)
6. Komander D, Lord CJ, Scheel H, et al., The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell 2008; 29: 451-464. (Pubitemid 351282537)
7. Yang W-L, Zhang X, Lin H-K,. Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. Oncogene 2010; 29: 4493-4503.
8. Saggar S, Chernoff KA, Lodha S, et al., CYLD mutations in familial skin appendage tumours. J Med Genet 2008; 45: 298-302. (Pubitemid 351685148)
9. Reiley WW, Jin W, Lee AJ, et al., Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 2007; 204: 1475-1485. (Pubitemid 46919884)
10. Liu H-H, Xie M, Schneider MD, et al., Essential role of TAK1 in thymocyte development and activation. Proc Natl Acad Sci U S A 2006; 103: 11677-11682. (Pubitemid 44182510)
11. Reiley W, Zhang M, Sun S-C,. Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem 2004; 279: 55161-55167. (Pubitemid 40066510)
12. Massoumi R, Chmielarska K, Hennecke K, et al., Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665-677.
13. Reiley WW, Zhang M, Jin W, et al., Regulation of T cell development by the deubiquitinating enzyme CYLD. Nature Immunol 2006; 7: 411-417.
14. Stokes A, Wakano C, Koblan-Huberson M, et al., TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell Signal 2006; 18: 1584-1594.
15. Gao J, Huo L, Sun X, et al., The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem 2008; 283: 8802-8809.
16. Stegmeier F, Sowa ME, Nalepa G, et al., The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci U S A 2007; 104: 8869-8874. (Pubitemid 47175403)
17. Tauriello DVF, Haegebarth A, Kuper I, et al., Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell 2010; 37: 607-619.
18. Chan EF, Gat U, McNiff JM, et al., A common human skin tumour is caused by activating mutations in beta-catenin. Nature Genet 1999; 21: 410-413. (Pubitemid 29159579)
19. DasGupta R, Fuchs E,. Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development 1999; 126: 4557-4568.
20. Rajan N, Elliott R, Clewes O, et al., Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours. Oncogene 2011; (in press).
21. Goette DK, McConnell MA, Fowler VR,. Cylindroma and eccrine spiradenoma coexistent in the same lesion. Arch Dermatol 1982; 118: 274-274.
22. Rasband WS. ImageJ [Internet]. US National Institutes of Health, Bethesda, Maryland, USA. 19972009; Available from: http://rsb.info.nih.gov/ij/ Accessed 1/11/2010
23. Sato H, Suzuki H, Toyota M, et al., Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis 2007; 28: 2459-2466. (Pubitemid 350238947)
24. Hirata H, Hinoda Y, Nakajima K, et al., Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin Cancer Res 2009; 15: 5678-5687.
25. Lang PG, McKelvey AC, Nicholson JH,. Three-dimensional reconstruction of the superficial multicentric basal cell carcinoma using serial sections and a computer. Am J Dermatopathol 1987; 9: 198-203. (Pubitemid 17161293)
26. Scheibe P, Braumann U-D, Kuska J-P, et al., Image-processing chain for a three-dimensional reconstruction of basal cell carcinomas. Exp Dermatol 2010; 19: 689-691.
27. Katoh M, Katoh M,. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007; 13: 4042-4045. (Pubitemid 47105963)
28. Lee J, Yoon YS, Chung JH,. Epigenetic silencing of the WNT antagonist DICKKOPF-1 in cervical cancer cell lines. Gynecol Oncol 2008; 109: 270-274.
29. Suzuki H, Toyota M, Carraway H, et al., Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 2008; 98: 1147-1156. (Pubitemid 351399804)
30. Aguilera O, Fraga MF, Ballestar E, et al., Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006; 25: 4116-4121. (Pubitemid 44024874)
31. Zhu F, Xia X, Liu B, et al., IKKalpha shields 14-3-3sigma, a G(2)/M cell cycle checkpoint gene, from hypermethylation, preventing its silencing. Mol Cell 2007; 27: 214-227. (Pubitemid 47058306)
32. Venza I, Visalli M, Tripodo B, et al., FOXE1 is a target for aberrant methylation in cutaneous squamous cell carcinoma. Br J Dermatol 2010; 162: 1093-1097.
33. Lodygin D, Yazdi AS, Sander CA, et al., Analysis of 14-3-3sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene 2003; 22: 5519-5524. (Pubitemid 37072207)
34. Sick S, Reinker S, Timmer J, et al., WNT and DKK determine hair follicle spacing through a reaction-diffusion mechanism. Science 2006; 314: 1447-1450. (Pubitemid 44871949)
35. Gujral TS, MacBeath G,. A system-wide investigation of the dynamics of Wnt signaling reveals novel phases of transcriptional regulation. PLoS ONE 2010; 5: e10024.
36. Spiegelman VS, Slaga TJ, Pagano M, et al., Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol Cell 2000; 5: 877-882.
37. Hoseong Yang S, Andl T, Grachtchouk V, et al., Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/β-catenin signaling. Nature Genet 2008; 40: 1130-1135.
38. Kriegl L, Horst D, Kirchner T, et al., LEF-1 expression in basal cell carcinomas. Br J Dermatol 2009; 160: 1353-1356.